Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 138.35% | 45.21% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 90.54% | 0.95% | |||
| Operating Income | -87.63% | -0.95% | |||
| Income Before Tax | -13.58% | -64.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.58% | -64.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -65.86% | -- | |||
| Net Income | -56.97% | -6.51% | |||
| EBIT | -87.63% | -0.95% | |||
| EBITDA | -96.74% | -1.08% | |||
| EPS Basic | -4.84% | -3.29% | |||
| Normalized Basic EPS | -70.94% | 39.94% | |||
| EPS Diluted | -4.84% | -3.29% | |||
| Normalized Diluted EPS | -70.94% | 39.94% | |||
| Average Basic Shares Outstanding | 49.72% | 3.13% | |||
| Average Diluted Shares Outstanding | 49.72% | 3.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||